- Home
- NVO vs NVS Comparison
NVO vs NVS Comparison
Compare NVO & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVO
- NVS
- Stock Information
- Founded
- NVO 1923
- NVS 1895
- Country
- NVO Denmark
- NVS Switzerland
- Employees
- NVO N/A
- NVS N/A
- Industry
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- NVS Biotechnology: Pharmaceutical Preparations
- Sector
- NVO Health Care
- NVS Health Care
- Exchange
- NVO Nasdaq
- NVS Nasdaq
- Market Cap
- NVO 278.0B
- NVS 242.8B
- IPO Year
- NVO N/A
- NVS 1991
- Fundamental
- Price
- NVO $56.32
- NVS $125.05
- Analyst Decision
- NVO Buy
- NVS Hold
- Analyst Count
- NVO 7
- NVS 6
- Target Price
- NVO $98.00
- NVS $123.67
- AVG Volume (30 Days)
- NVO 30.0M
- NVS 1.4M
- Earning Date
- NVO 08-06-2025
- NVS 07-17-2025
- Dividend Yield
- NVO 2.19%
- NVS 2.07%
- EPS Growth
- NVO 24.25
- NVS N/A
- EPS
- NVO 3.93
- NVS 6.85
- Revenue
- NVO $49,108,936,497.00
- NVS $55,186,000,000.00
- Revenue This Year
- NVO $13.92
- NVS $8.96
- Revenue Next Year
- NVO $14.04
- NVS $2.34
- P/E Ratio
- NVO $14.34
- NVS $18.28
- Revenue Growth
- NVO 20.91
- NVS 12.95
- 52 Week Low
- NVO $45.05
- NVS $96.06
- 52 Week High
- NVO $139.74
- NVS $128.03
- Technical
- Relative Strength Index (RSI)
- NVO 50.25
- NVS 61.49
- Support Level
- NVO $53.83
- NVS $113.48
- Resistance Level
- NVO $55.48
- NVS $128.03
- Average True Range (ATR)
- NVO 1.20
- NVS 1.36
- MACD
- NVO 1.39
- NVS 0.80
- Stochastic Oscillator
- NVO 84.80
- NVS 79.48
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.